

October 12, 2016

## Faculty Opportunities

**Multi-Site Pilot and Feasibility Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34)** - As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA and NIAAA join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services. Companion Funding Opportunity is [PAR-16-455, R01](#) Research Project Grant. **Application Due Date(s): December 15, 2016; July 18, 2017** <http://grants.nih.gov/grants/guide/pa-files/PAR-16-456.html>

**International Research Scientist Development Award (IRSDA) (K01)** - The purpose of this award is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank, including "low-income," "lower-middle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from early-career investigators from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors. Companion Funding Opportunity is [PAR-17-001K43](#) Emerging Global Leader Award. **Application Due Date(s): March 2, 2017; March 7, 2018; March 7, 2019.** <http://grants.nih.gov/grants/guide/pa-files/PAR-17-002.html>

**DHHS Funds for Support for Expectant and Parenting Teens, Women, Fathers and their Families** - The Funding Opportunity Announcement will provide competitive grant awards under the authority of Sections 10211-10214 of the Patient Protection and Affordable Care Act (Public Law 111-148; Affordable Act). The Pregnancy Assistance Fund (PAF) grant program provides support for States and tribes to develop and implement programs to improve the educational, health, and social outcomes for expectant and parenting teens, women, fathers and their families. The PAF aims to strengthen access to and completion of education (secondary and postsecondary); improve child and maternal health outcomes; improve pregnancy planning and spacing and reduce the likelihood of repeat teen pregnancies; increase parenting skills for mothers, fathers, and families; strengthen co-parenting relationships and marriage where appropriate, increase positive paternal involvement; decrease intimate partner violence; and raise awareness of available resources. For purposes of this funding announcement, the priority populations and settings include both women and men who are expecting a child, teens of high-school age, students enrolled in institutions of higher education and their families including, but not limited to spouses, partners, and children. **Anticipated Application Due Date: March 31, 2017.** <http://www.grants.gov/web/grants/view-opportunity.html?oppld=289326>

**HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)** - This FOA will support biphasic (i.e., two stage, multi-method) research projects that inform community response and promote comprehensive, integrated approaches to prevent HIV and hepatitis C virus (HCV) infection, along with associated comorbidities such as hepatitis B virus (HBV) infection and sexually transmitted diseases (STDs), among people who inject drugs (PWID) in rural US communities.

Opioid injection and its consequences (e.g., HIV, HCV, HBV, STDs and overdose) are the primary foci here. These projects should yield evidence of the effectiveness of community response models and best practices in responding to opioid injection epidemics that can be implemented by public health systems in similar rural communities in the US. **Application Due Date: January 10, 2017.**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-17-014.html>

**Secondary Analyses of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) -**

The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection; it will not support the collection of new data. **Application Due Date: February 24, 2017.**

<http://grants.nih.gov/grants/guide/pa-files/PA-17-004.html>

**PCORI Clinical Strategies for Managing and Reducing Long-Term Opioid Use for Chronic Pain -** PCORI is reopening this funding initiative to support patient-centered comparative clinical effectiveness research (CER) that addresses important questions regarding clinical strategies for managing and reducing long-term opioid use for chronic pain. Through this PCORI Funding Announcement (PFA), PCORI seeks to fund studies that have a sufficient sample size to address the research questions noted below and that will generate information that is readily generalizable to the broader population. The two priority research questions are: 1. Among patients with chronic noncancer pain on moderate/high-dose long-term opioid therapy, what is the comparative effectiveness of strategies for reducing/eliminating opioid use while managing pain? 2. Among patients with chronic noncancer pain on moderate/low-dose long-term opioid therapy, what are the comparative effectiveness and harms of strategies used to limit dose escalation?

**Application Due Date(s): Letter of Intent Due November 1, 2016. Invited Full Applications Due February 7, 2017.** <http://www.pcori.org/funding-opportunities/announcement/clinical-strategies-managing-and-reducing-long-term-opioid-use-2016>

**Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21) -** This Funding Opportunity Announcement (FOA) supports planning, design and initial pilots for locally relevant and catalytic research on non-communicable diseases (NCDs) or injury in low and middle-income countries (LMICs). Research addressing multiple NCDs and their risk factors and research addressing NCDs as comorbidities for/with infectious diseases including HIV/AIDS is encouraged. Scientists in the United States (U.S.) or upper middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Income categories used are defined by the World Bank. Pilot activities and research are expected to inform the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address NCDs and injury throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project. For applications on any research topic related to the brain, nervous system, mental health and substance abuse please see the companion FOA: [PAR-14-331](#) "Global brain and nervous system disorders research across the lifespan (R21)". **Application Due Date: February 24, 2016; February 22, 2017.**

<http://grants.nih.gov/grants/guide/pa-files/PA-16-052.html>

**Applied Research Toward Zero Suicide Healthcare Systems (R01)** - This funding opportunity announcement (FOA) is intended to support applied research that advances the National Action Alliance for Suicide Prevention's "Zero Suicide" goal of preventing suicide events (attempts, deaths) among individuals receiving treatment within health care systems. Zero Suicide is a commitment to the prevention of suicide among individuals served by health care systems and is also a specific set of health care strategies and tools intended to eliminate suicide events. Research is needed to implement effective and comprehensive suicide prevention strategies in a variety of settings, including behavioral health and substance abuse outpatient clinics, emergency departments and crisis care programs and centers, hospitals, and integrated primary care programs. To achieve the aspirational goal of zero suicide events within healthcare settings, research is needed to improve health care approaches for the following: systematic approaches to suicide risk detection (acute or long term); appropriate risk documentation and follow-up care that is practical and effective; interventions earlier in the course of suicide risk trajectories that reduce incident suicide events in care systems; identification of effective service delivery components that work as safety nets to prevent suicidal events; and identification of service delivery policies and practices that support and maintain "Zero Suicide" goals and reduce suicide events. **Application Due Date: November 2, 2016.** <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-16-800.html>

**Pfizer Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Dietary Intakes, Safety, and Public Health Value of Calcium** - It is Pfizer's intent to support projects that focus on increasing the awareness and understanding of: 1) gaps in dietary intake of calcium (specifically LATAM and APAC); 2) the safety of calcium supplementation with or without vitamin D, with respect to cardiovascular disease; and 3) the public health value of closing dietary gaps in calcium. Target learner audiences include: 1) healthcare professionals with a focus on prevention and treatment of osteoporosis and 2) General practitioners. All activity types will be considered through this CGA including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials including published proceedings. An activity taking place alongside the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) is of particular interest. **Application Due Date: November 11, 2016.** [http://www.pfizer.com/files/IGLC\\_CGA16DS1\\_DietarySupplementsCalcium.pdf](http://www.pfizer.com/files/IGLC_CGA16DS1_DietarySupplementsCalcium.pdf)

**Outstanding New Environmental Scientist (ONES) Award (R01)** - The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding of environmental exposure effects on people's health. Only one application per School or College within a University will be accepted. **Application Due Date: February 26, 2016.** <https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-15-020.html>

**Michael & Susan Dell Foundation** - The Foundation only accepts unsolicited proposals for specific areas within the education, family economic stability and childhood health sectors in select countries where it works, namely the United States, India and South Africa. The Foundation seeks to fund projects that directly serve or impact children living in urban poverty, particularly in the areas of education, family economic stability (including microfinance) and childhood health. **Application Due Date: Applications Accepted on a Rolling Basis.** <https://www.msdf.org/apply/>

**AARP Foundation Unsolicited Grants** - AARP Foundation is always looking for new ways to better serve the vulnerable 50+ population. While the majority of awards are made through open grant competition,

the Foundation recognizes that there are ideas outside of the scope of its grant opportunities. The Foundation invites organizations with innovative, evidence-based, concepts and programs to apply via its unsolicited application process. **Application Due Date: Applications Accepted on a Rolling Basis.** <http://www.aarp.org/aarp-foundation/grants/current-opportunities.html>

**Laura and John Arnold Foundation (LJAF) Prescription Drugs** - LJAF's core objective is to address our nation's most pressing and persistent challenges using evidence-based, multi-disciplinary approaches. LJAF is seeking Letters of Interest from organizations with innovative ideas for how to maximize access to, and affordability of, prescription drugs while preserving incentives for innovation in drug development. Specifically, LJAF is interested in ideas for how to address the use of prescription drug coupons, which, in some instances, have been shown to increase health care system costs. **Application Due Date: December 15, 2016.** <http://www.arnoldfoundation.org/letters-of-interest/>